Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Health Market Science (King of Prussia, PA) a commercial-stage biopharma and healthcare data and analytics provider, closed a $6.1M Series B financing. Participants include Cross Atlantic Capital Partners and Edison Venture Fund.

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Metamark Genetics (Cambridge, MA) a development-stage molecular diagnostics company focused on prognostic assays for early-stage cancers, closed a $22M Series B financing. Participants may have included Perseus.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

BioScale (Cambridge, MA) a commercial-stage therapeutic and diagnostics protein biomarker analytics device company, closed a $25M Series D financing. Participants include Morningside Venture, New Science Ventures, WFD Ventures and F2 Ventures.